Business
ValiRx partners with Clarity Imaging
ValiRx partners with Clarity Imaging.
About this update from Valirx Plc
[{"type":"text","content":"\n \nFinal: 12th June 2007 - 12pm\n\n ValiRx Plc \n (\"ValiRx\" or the \"Company\") \n\n ValiRx Plc partners with Clarity Imaging to Cooperate \n on Future Technology Transfers \n\nValiRx Plc (AIM: VAL), a biopharmaceutical development company that is building\na portfolio of complementary cancer-related therapeutic and diagnostic\ntechnologies, today announces that on 25th May 2007, it signed a strategic\nalliance agreement with Clarity Imaging International, Inc (OTCBB: ECSI.OB), a\nUS company that offers emerging technologies to the medical community. Under\nthe agreement, both parties will cooperate and agree terms to exploit\ntechnology transfer initiatives between the U.S. and Europe in the future.\n\nSpecifically, both companies will look to agree to cross license certain of\ntheir technologies for distribution into the other company's market. To date,\nboth companies have identified technology areas, covered by ValiRx's patents,\nto be exploited under this agreement, but the terms and conditions of this\nexploitation have yet to be formalized. Further updates will be provided to the\nmarket when these terms are agreed.\n\nClarity Imaging, through an agreement with Bridgetech Holdings International,\nis currently targeting specific diagnostics and prognostics markets in the U.S.\nwith products from Greater China. It has created strategic relationships in the\nU.S. healthcare supply chain market which it believes maximizes product\nexposure. Furthermore, Clarity Imaging is also exploiting ongoing relationships\nthrough Bridgetech including MD Anderson Cancer Centers and other cancer\ncenters.\n\n\"We are pleased and proud to be affiliated with ValiRx,\" stated John Relic,\nPresident and COO of Clarity Imaging. \"The collaboration allows Clarity to\npotentially gain access to the European biopharmaceutical market, furthering\nour growth in the medical diagnostic arena. \"\n\nDr Satu Vainikka, CEO of ValiRx, said: \"We are developing a portfolio of new\ntechnologies in the therapeutics and diagnostic markets, with a specific focus\non cancer. We are delighted to be partnering with an organization such as\nClarity that has the potential to bring our technologies to US markets.\"\n\n ---ENDS--- \n\nFor Further Information\n\nValiRx:\n\nDr Satu Vainikka (CEO) +44 203 008 4416\nToby Hall / Jade Mamarbachi (gth media) +44 207 153...